Bacterial Gastroenteritis Medication
- Author: Jennifer Lynn Bonheur, MD; Chief Editor: Julian Katz, MD more...
Medication Summary
The goals of pharmacotherapy in cases of gastroenteritis are to reduce morbidity and to prevent complications. The following is a list of standard antimicrobial therapies for bacterial gastroenteritis (although, as previously stated, many conditions are self-limited and require no therapy):
- Aeromonas species - Use cefixime and most third-generation and fourth-generation cephalosporins
- Bacillus species - No antibiotics are necessary for self-limited gastroenteritis, but vancomycin and clindamycin are first-line drugs for severe disease
- Campylobacter species - Erythromycin may shorten illness duration and shedding; delaying therapy beyond 4 days from onset of symptoms appears to produce no clinical benefit
- C difficile - Discontinue potential causative antibiotics; if antibiotics cannot be stopped or this does not resolve diarrhea, use oral metronidazole or vancomycin (vancomycin is reserved for seriously ill patients whose condition does not respond to metronidazole)
- C perfringens - Do not treat with antibiotics
- Listeria species - No antibiotics are needed unless invasive disease occurs; ampicillin and Bactrim are first-line drugs for invasive disease
- Plesiomonas species - Use trimethoprim-sulfamethoxazole or any cephalosporin
- V cholerae - Tetracycline is the usual antibiotic of choice, but resistance to it is increasing; other antibiotics that are effective when V cholerae is sensitive to tetracycline include cotrimoxazole, erythromycin, doxycycline, chloramphenicol, and furazolidone
- Yersinia species - Treatment (ie, trimethoprim-sulfamethoxazole, fluoroquinolones, aminoglycosides) does not shorten the disease duration and should be reserved for complicated cases
E coli
Antibiotic treatment appears to increase the likelihood of HUS developing. Consider antibiotics if diarrhea is moderate or severe. Trimethoprim-sulfamethoxazole is a first-line drug, but use a parenteral second-generation or third-generation cephalosporin for systemic complications.
Salmonella species
Antibiotic treatment prolongs the carrier state and is associated with relapse; thus, treatment is not indicated for nontyphoid, uncomplicated diarrhea. Consider treatment for infants younger than 3 months and for high-risk patients, such as patients who are immunocompromised or who have sickle cell disease.
Ampicillin is recommended for drug-sensitive strains. Trimethoprim-sulfamethoxazole, fluoroquinolones, or third-generation cephalosporins (fluoroquinolones are not recommended for use in children) are also acceptable alternatives. S typhimurium T104 is a multidrug-resistant organism. Sensitivities from the cultured specimens are important to guide therapy.
Shigella species
Antibiotic treatment may shorten illness duration and shedding but does not prevent complications. Most mild infections will recover without antibiotics. Moderate to severe cases should be treated with antibiotics. Ampicillin is preferred for drug-sensitive strains. For ampicillin-resistant strains or in cases of penicillin allergy, trimethoprim-sulfamethoxazole is the drug of choice, although resistance does occur. Fluoroquinolones may be considered in patients with highly resistant organisms.
Antibiotics
Class Summary
Along with the immune system, antibiotics help to destroy offending organisms.
Cefixime (Suprax)
Cefixime is a potent, long-acting oral cephalosporin with increased gram-negative coverage. It arrests bacterial growth by binding to 1 or more penicillin-binding proteins.
Ceftriaxone (Rocephin)
Ceftriaxone is a third-generation parenteral antibiotic with wide coverage, including of gram-negative bacilli. It arrests bacterial growth by binding to 1 or more penicillin-binding proteins.
Cefotaxime (Claforan)
Cefotaxime is a third-generation parenteral antibiotic with wide coverage, including of gram-negative bacilli. It arrests bacterial cell wall synthesis, which, in turn, inhibits bacterial growth.
Erythromycin (E.E.S., EryPed, Erythrocin, Ery-Tab)
Erythromycin is an old bacteriostatic macrolide with activity against most gram-positive organisms and atypical respiratory organisms. It is useful for Campylobacter and Vibrio enteritis. Nausea is a common adverse effect and may be tolerated poorly in some patients. Enteric-coated tablets reduce nausea.
Trimethoprim-sulfamethoxazole (Bactrim, Bactrim DS, Septra DS)
This is a folate synthesis blocker that has wide antibiotic coverage.
Vancomycin (Vancocin)
Vancomycin therapy is a powerful treatment for antibiotic-associated colitis. Vancomycin is indicated for patients who cannot receive or whose condition has not responded to penicillins and cephalosporins or who are infected with resistant staphylococci.
To avoid toxicity, the current recommendation is to assay trough levels after the third dose drawn 0.5 hour before the next dosing. Use creatinine clearance to adjust the dose in patients diagnosed with renal impairment.
Vancomycin is used in conjunction with gentamicin for prophylaxis in patients allergic to penicillin who are undergoing a gastrointestinal or genitourinary procedure.
Rifaximin (Xifaxan)
Rifaximin is a nonabsorbed (< 0.4%), broad-spectrum antibiotic specific for enteric pathogens of the gastrointestinal tract (ie, gram-positive, gram-negative, aerobic, anaerobic). Rifampin is a structural analogue. It binds to the beta subunit of bacterial deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase, thereby inhibiting RNA synthesis. It is indicated for E coli (enterotoxigenic and enteroaggregative strains) associated with travelers' diarrhea.
Salminen S, Isolauri E, Onnela T. Gut flora in normal and disordered states. Chemotherapy. 1995;41 suppl 1:5-15. [Medline].
Marks MI. Infectious diarrhea: introduction and commentary. Pediatr Ann. Oct 1994;23(10):526-7. [Medline].
Liebelt EL. Clinical and laboratory evaluation and management of children with vomiting, diarrhea, and dehydration. Curr Opin Pediatr. Oct 1998;10(5):461-9. [Medline].
Hamer DH, Gorbach SL. Infectious diarrhea and bacterial food poisoning. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisinger and Fordtran's Gastrointestinaland Liver Disease. 6th ed. Philadelphia, Pa: WB Saunders; 1998:1594-1632.
Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. Nov 15 2007;64(22):2359-63. [Medline].
Steffen R, Collard F, Tornieporth N, et al. Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. JAMA. Mar 3 1999;281(9):811-7. [Medline]. [Full Text].
Streit JM, Jones RN, Toleman MA, Stratchounski LS, Fritsche TR. Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003). Int J Antimicrob Agents. May 2006;27(5):367-75. [Medline].
Vital Signs: Preventing Clostridium difficile Infections. MMWR Morb Mortal Wkly Rep. Mar 9 2012;61:157-62. [Medline].
World Health Organization. Cholera: fact sheet no. 107. November 2008. Available at http://www.who.int/mediacentre/factsheets/fs107/en/. Accessed February 19, 2009.
Lee LA, Gerber AR, Lonsway DR, et al. Yersinia enterocolitica O:3 infections in infants and children, associated with the household preparation of chitterlings. N Engl J Med. Apr 5 1990;322(14):984-7. [Medline].
Centers for Disease Control and Prevention. Yersinia enterocolitica. October 25, 2005. Available at http://www.cdc.gov/ncidod/dbmd/diseaseinfo/yersinia_g.htm. Accessed February 18, 2009.
Centers for Disease Control and Prevention (CDC). Deaths from gastroenteritis double. Available at http://www.cdc.gov/media/releases/2012/p0314_gastroenteritis.html.
Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology. May 2006;130(6):1588-94. [Medline].
Calbo E, Freixas N, Xercavins M, Riera M, Nicolás C, Monistrol O, et al. Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: epidemiology and control. Clin Infect Dis. Mar 2011;52(6):743-9. [Medline].
Cody SH, Abbott SL, Marfin AA, et al. Two outbreaks of multidrug-resistant Salmonella serotype typhimurium DT104 infections linked to raw-milk cheese in Northern California. JAMA. May 19 1999;281(19):1805-10. [Medline]. [Full Text].
World Health Organization. Drug-resistant Salmonella: fact sheet no. 139. Revised April 2005. Available at http://www.who.int/mediacentre/factsheets/fs139/en/. Accessed February 19, 2009.
Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. Jan 2000;30(1):54-60. [Medline].
Simakachorn N, Pichaipat V, Rithipornpaisarn P, et al. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J Pediatr Gastroenterol Nutr. Jan 2000;30(1):68-72. [Medline].
Duggan C, Nurko S. "Feeding the gut": the scientific basis for continued enteral nutrition during acute diarrhea. J Pediatr. Dec 1997;131(6):801-8. [Medline].
Guandalini S, Dincer AP. Nutritional management in diarrhoeal disease. Baillieres Clin Gastroenterol. Dec 1998;12(4):697-717. [Medline].
Sullivan PB. Nutritional management of acute diarrhea. Nutrition. Oct 1998;14(10):758-62. [Medline].
[Best Evidence] Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al, for the Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. Jan 5 2006;354(1):11-22. [Medline]. [Full Text].
DuPont HL, The Practice Parameters Committee of the American College of Gastroenterology. Guidelines on acute infectious diarrhea in adults. Am J Gastroenterol. Nov 1997;92(11):1962-75. [Medline].
Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. Dec 2007;5(12):1418-23. [Medline].
Gibreel A, Taylor DE. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother. Aug 2006;58(2):243-55. [Medline]. [Full Text].
Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol. 2007;51(12):1209-14. [Medline]. [Full Text].
Mines D, Stahmer S, Shepherd SM. Poisonings: food, fish, shellfish. Emerg Med Clin North Am. Feb 1997;15(1):157-77. [Medline].
Nataro JP, Steiner T, Guerrant RL. Enteroaggregative Escherichia coli. Emerg Infect Dis. Apr-Jun 1998;4(2):251-61. [Medline].
Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med. Jun 2006;119(6 suppl 1):S20-8; discussion S62-70. [Medline].
Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ. Feb 27 1999;318(7183):565-6. [Medline]. [Full Text].
Trachtman H, Christen E. Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome. Curr Opin Pediatr. Apr 1999;11(2):162-8. [Medline].
Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. Jun 29 2000;342(26):1930-6. [Medline]. [Full Text].
| Stool Characteristics | Small Bowel | Large Bowel |
| Appearance | Watery | Mucus and/or blood |
| Volume | Large | Small |
| Frequency | Increased | Increased |
| Blood | Possibly heme-positive but never gross blood | Possibly grossly bloody |
| pH | Possibly < 5.5 | >5.5 |
| Reducing substances | Possibly positive | Negative |
| White blood cell (WBC) count | < 5/high-power field (HPF) | Possibly >10/HPF |
| Serum WBC count | Normal | Possible leukocytosis, bandemia |
| Organisms | Preformed toxins: Bacillus species, Staphylococcus aureus | Invasive bacteria: E coli and Shigella, Salmonella, Campylobacter, Yersinia, Aeromonas, and Plesiomonas species |
| Toxic bacteria: E coli, cholera, C perfringens, Vibrio species, Listeria monocytogenes | Toxic bacteria: C difficile | |
| Other causes: rotavirus, adenovirus, calicivirus, astrovirus, Norwalk virus, and Giardia and Cryptosporidium species | Other causes: Entamoeba species |
| Organism | Incubation | Duration | Vomiting | Fever | Abdominal Pain |
| Aeromonas species | None | 0-2 weeks | +/- | +/- | No |
| Bacillus species | 1-16 hours | 1-2 days | Yes | No | Yes |
| Campylobacter species | 2-4 days | 5-7 days | No | Yes | Yes |
| C difficile | Variable | Variable | No | Few | Few |
| C perfringens | 0-1 | 1 day | Mild | No | Yes |
| Enterohemorrhagic E coli | 1-8 days | 3-6 days | No | +/- | Yes |
| Enterotoxigenic E coli | 1-3 days | 3-5 days | Yes | Low | Yes |
| Listeria species | 20 hours | 2 days | Few | Yes | +/- |
| Plesiomonas species | None | 0-2 weeks | +/- | +/- | +/- |
| Salmonella species | 0-3 days | 2-7 days | Yes | Yes | Yes |
| Shigella species | 0-2 days | 2-7 days | No | High | Yes |
| S aureus | 2-6 hours | 1 day | Yes | No | Yes |
| Vibrio species | 0-1 days | 5-7 days | Yes | No | Yes |
| Y enterocolitica | 0-6 | 1-46 days | Yes | Yes | Yes |
| Organism | Detection Method | Microbiologic Characteristics |
| Aeromonas species | Blood agar | Oxidase-positive, flagellated GNB |
| Bacillus species | Blood agar | Facultatively aerobic, spore-forming GPR; beta hemolytic; reduces nitrates; ferments carbohydrates |
| Campylobacter species | Skirrow agar | Rapidly motile, curved GNR; Campylobacter jejuni 90% of infections, Campylobacter coli 5% of infections |
| C difficile | CCFE agar, EIA for toxin, LA for protein | Anaerobic, spore-forming GPR; toxin-mediated diarrhea; produces pseudomembranous colitis |
| C perfringens | None available | Anaerobic, spore-forming GPR; toxin-mediated diarrhea |
| E coli | MacConkey, EMB, or SM agar | Lactose-producing GNR |
| Listeria species | Blood agar | Flagellated GPB |
| Plesiomonas species | Blood agar | Oxidase-positive GNR |
| Salmonella species | Blood, MacConkey, EMB, XLD, or HE agar | Nonlactose, non–H2S-producing GNR |
| Shigella species | Blood, MacConkey, EMB, XLD, or HE agar | Nonlactose and H2S-producing GNR; verotoxin (neurotoxin) |
| Staphylococcus species | Blood agar | Heat-stable, preformed toxin-mediated GPC |
| Vibrio species | Blood or TCBS agar | Oxidase-positive, motile, curved GNB |
| Y enterocolitica | CIN agar | Nonlactose-producing, oval GNR |
| CCFE = cycloserine-cefoxitin-fructose-egg; CIN = cefsulodin-irgasan-novobiocin; EIA= enzyme immunoassay; EMB = e-methylene blue; GNB = gram-negative bacillus; GNR = gram-negative rod; GPB = gram-positive bacillus; GPC = gram-positive cocci; GPR = gram-positive rod; H2S = hydrogen sulfide; HE = Hektoen enteric; LA = latex agglutination; SM = Sorbitol-MacConkey; TCBS = thiosulfate-citrate-bile-sucrose; XLD = xylose-lysine-deoxycholate. | ||
Print
